Our team knows eye care

We have assembled a team with extensive experience developing and commercializing leading ophthalmic products and therapies.

JEFFREY NAU, PHD, MMS President and Chief Executive Officer

Jeffrey Nau, PhD, MMS

President and Chief Executive Officer

Jeff has built his career on developing novel, innovative therapies for diseases of the eye, with over 20 years of experience working with biotechnology, pharmaceutical, and medical device companies. Most recently, he was VP, Clinical and Medical Affairs, at Ophthotech. Prior to that, Jeff was a Medical Science Director at Genentech working on the development and launch of multiple indications for Lucentis®, a transformative drug for retinal diseases. Jeff has helped raise more than $250 million in equity for innovative startups such as Genaera Corporation, Acuity Pharmaceuticals, and NeoVista, Inc. He holds numerous patents and peer-reviewed publications. Jeff has a Ph.D. in Public Health and Epidemiology from Walden University, a M.S. in Medical Science from MCP Hahnemann School of Medicine, and a B.S. in Biology from Stony Brook University.

close up of a man leaning against a wall

Daniel Lochner, MBA

Chief Financial Officer

Daniel has nearly 15 years of experience in healthcare investing. Prior to joining Oyster Point Pharma, Daniel held positions of increasing responsibility in equity investing and fund management at Goldman Sachs Asset Management. Most recently he was a Managing Director and Portfolio Manager at Goldman Sachs, where he was a healthcare equity investor for various fund strategies. As a healthcare investor, Daniel focused on biotechnology, pharmaceutical, medical device and healthcare services companies and invested in a range of therapeutic categories, including ophthalmology. Daniel received an Executive M.B.A. from Columbia University and a B.A. in Economics from the University of Richmond.

close up of a man leaning against a wall

John Snisarenko, MBA

Chief Commercial Officer

John has 30 years of commercial experience in the pharmaceutical industry, including major ophthalmology businesses. He has a proven track record in taking programs from development to successful commercialization, and helping businesses achieve high growth. Prior to joining Oyster Point, John spent the past 2 years at Shire (now Takeda) as Group Vice President and Head of its ophthalmic business. During that time, he led a large, multidisciplinary team accountable for the growth of Shire’s first ophthalmic therapeutic, Xiidra ®, for treatment of dry eye. He served as a member of the commercial leadership team at Shire and played a key role in the divestiture of the ophthalmic business to Novartis Pharma. Prior to joining Shire, John led commercial activities for Genentech’s ophthalmology (Lucentis ®) and rheumatology (Rituxan ®, Actemra ®) franchises for 10 years. John has also held various positions of increasing responsibility at CIBA Vision/Novartis Pharma. He holds a B.Sc. in Biochemistry and an MBA in Marketing and International Business from McGill University in Montreal, Canada.

close up of women leaning against a wall

Jill Andersen, JD

General Counsel, Corporate Secretary and Chief Compliance Officer

Jill has over 20 years of legal, compliance and leadership experience in the pharmaceutical industry, government and private practice. Jill joined Oyster Point from Bristol Myers Squibb, post-acquisition of Celgene Corporation where she was Vice President, Head of Legal for the Inflammation & Immunology global franchise. Prior to joining Celgene, Jill held various positions of increasing responsibility at Novartis, including senior leadership roles in legal and compliance at Novartis Pharmaceuticals Corporation and Novartis Consumer Health. Jill has developed a track record for being an integral business partner while building key legal and compliance functions necessary to support and sustain growing and diversifying businesses. Jill has worked extensively on matters related to product development, marketing approval and commercialization, including product launches across multiple therapeutic areas. Her experience also spans corporate governance, corporate transactions, IP, litigation and investigations. Prior to joining the pharmaceutical industry, Jill was an Assistant U.S. Attorney for the District of New Jersey and was a litigation associate at the law firm of Davis Polk & Wardwell. She holds a J.D. from Wake Forest University, School of Law and a B.S. in Finance from Boston College.

Eric Carlson, PHD

Chief Scientific Officer

Eric has over 20 years of experience in ophthalmology with expertise in pre-clinical discovery through global clinical development and launch for pharmaceuticals, medical devices, over-the-counter therapeutics and generics. Prior to joining Oyster Point Pharmaceuticals, he was Chief Scientific Officer for Akorn Pharmaceuticals, Global Head of R&D for Aerie Pharmaceuticals and Senior Global Program Head and Therapeutic Unit Head for Novartis and Alcon leading all phases of development for the Ophthalmology Disease Area. He holds numerous patents and peer-reviewed publications and served 6 years on the ARVO Foundation Board of Governors. Prior to joining industry, Eric was a member of the faculty at Case Western Reserve University in the Department of Ophthalmology and Visual Sciences, completed his postdoctoral fellowship at the Cleveland Clinic Cole Eye Institute and holds a Ph.D. in Molecular and Cellular Biology from the University of Cincinnati, College of Medicine earned for his work in the Department of Ophthalmology and a B.A. in pre-medical Biology from Thiel College.

Marian Macsai, MD

Chief Medical Officer, Medical Affairs

Marian Macsai most recently held a key leadership position as Chief of the Division of Ophthalmology for NorthShore University Health System, where she built the division from one doctor in one office to 19 MDs in 7 offices across the Northern Suburbs of Chicago. Dr. Macsai also serves as a Clinical Professor of Ophthalmology University of Chicago Pritzker School of Medicine. Prior to her role with NorthShore University Health System, Dr. Macsai led as a Professor of Ophthalmology Vice Chair Department of Ophthalmology for Northwestern University Feinberg School of Medicine. She has served as the President of the Cornea Society, and Chair of the Eye Bank Association of America. In addition, Dr. Macsai was on the Ophthalmic Devices Advisory Panel of the FDA, the Advisory Committee on Blood and Tissue Safety and Availability, and she co-chairs a committee for the World Health Organization on Biovigilance and Surveillance in Transplantation of Medical Products of Human Origin. Dr. Macsai recently was honored with the American Academy of Ophthalmology Lifetime Fellow Award.

George Donato

George Donato, MBA

Senior Vice President, CMC and Operations

George is an accomplished Pharmaceutical Operations and Technical CMC executive with over 25 years delivering exceptional results in new product launches, product development and supply chain. Most recently he was the Sr. Vice President, Global Operations for Iroko Pharmaceuticals and prior to that he was a New Product Leader at Pfizer. He has successfully launched several new products globally for Iroko, Pfizer and Wyeth. George is adept at balancing regulatory, quality, technical, supply and commercial needs to continuously improve process performance, quality and profitability. George graduated from Widener University with an M.B.A. and a B.S. in Engineering.

Loni Da Silva, MS, RAC

Senior Vice President of Regulatory Affairs

Loni has over 30 years of leadership experience in global regulatory affairs and strategic drug development, with more than 20 years in the ophthalmic space. She began her career at Hoffman La-Roche, and most recently served as SVP, Global Regulatory Affairs for Ophthotech, where she worked on wet and dry AMD. Loni has led global regulatory affairs for 3 start-ups and IPOs including Eyetech, Pharmasset, and Ophthotech. In addition to the ophthalmic space, her experience also includes oncology, antivirals, anti-infectives, hematology, pain management, and cardiology. Loni received her B.S. in microbiology from Penn State University and a M.S. in regulatory affairs from Long Island University.